Efficacy and Safety of Oral GnRH antagonists in Patients with Uterine Fibroids: A Systematic Review
CONCLUSION: Among oral GnRH antagonists, relugolix, elagolix, and linzagolix were safe in patients with uterine fibroids. These drugs, alone and in combination with estradiol/norethindrone acetate (E2/NETA), showed significantly better efficacy than placebo in improving bleeding, discomfort, uterine/leiomyoma sizes, and quality of life in premenopausal patients with symptomatic uterine fibroids. However, more randomized double blind multicenter clinical trials are needed to confirm these results and to see long-term benefits.PMID:36368594 | DOI:10.1016/j.jogc.2022.10.012 (Source: Journal of Obstetrics and Gynaecology Canada : JOGC)
Source: Journal of Obstetrics and Gynaecology Canada : JOGC - November 11, 2022 Category: OBGYN Authors: Rabiya Niaz Memoona Saeed Huda Khan Muhammad Ashar Ali Ahmed Irshad Marium Faiz Alaa Irshad Faraeha Fatima Sameer Altaf Tunio Wajeeha Aiman Source Type: research
Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas
CONCLUSION: Improvements in heavy menstrual bleeding and anemia and reduction of uterine leiomyoma-associated symptom burden were sustained through up to 52 weeks of treatment with relugolix combination therapy in women with uterine leiomyomas. No new safety concerns were identified, and BMD was maintained.CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov, NCT03049735; NCT03103087; NCT03412890.FUNDING SOURCE: Myovant Sciences GmbH.PMID:36357960 | DOI:10.1097/AOG.0000000000004988 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - November 11, 2022 Category: OBGYN Authors: Ayman Al-Hendy Andrea S Lukes Alfred N Poindexter Roberta Venturella Claudio Villarroel Laura McKain Yulan Li Rachel B Wagman Elizabeth A Stewart Source Type: research
Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas
CONCLUSION: Improvements in heavy menstrual bleeding and anemia and reduction of uterine leiomyoma-associated symptom burden were sustained through up to 52 weeks of treatment with relugolix combination therapy in women with uterine leiomyomas. No new safety concerns were identified, and BMD was maintained.CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov, NCT03049735; NCT03103087; NCT03412890.FUNDING SOURCE: Myovant Sciences GmbH.PMID:36357960 | DOI:10.1097/AOG.0000000000004988 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - November 11, 2022 Category: OBGYN Authors: Ayman Al-Hendy Andrea S Lukes Alfred N Poindexter Roberta Venturella Claudio Villarroel Laura McKain Yulan Li Rachel B Wagman Elizabeth A Stewart Source Type: research
Efficacy and Safety of Oral GnRH antagonists in Patients with Uterine Fibroids: A Systematic Review
CONCLUSION: Among oral GnRH antagonists, relugolix, elagolix, and linzagolix were safe in patients with uterine fibroids. These drugs, alone and in combination with estradiol/norethindrone acetate (E2/NETA), showed significantly better efficacy than placebo in improving bleeding, discomfort, uterine/leiomyoma sizes, and quality of life in premenopausal patients with symptomatic uterine fibroids. However, more randomized double blind multicenter clinical trials are needed to confirm these results and to see long-term benefits.PMID:36368594 | DOI:10.1016/j.jogc.2022.10.012 (Source: Journal of Obstetrics and Gynaecology Canada : JOGC)
Source: Journal of Obstetrics and Gynaecology Canada : JOGC - November 11, 2022 Category: OBGYN Authors: Rabiya Niaz Memoona Saeed Huda Khan Muhammad Ashar Ali Ahmed Irshad Marium Faiz Alaa Irshad Faraeha Fatima Sameer Altaf Tunio Wajeeha Aiman Source Type: research
Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas
CONCLUSION: Improvements in heavy menstrual bleeding and anemia and reduction of uterine leiomyoma-associated symptom burden were sustained through up to 52 weeks of treatment with relugolix combination therapy in women with uterine leiomyomas. No new safety concerns were identified, and BMD was maintained.CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov, NCT03049735; NCT03103087; NCT03412890.FUNDING SOURCE: Myovant Sciences GmbH.PMID:36357960 | DOI:10.1097/AOG.0000000000004988 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - November 11, 2022 Category: OBGYN Authors: Ayman Al-Hendy Andrea S Lukes Alfred N Poindexter Roberta Venturella Claudio Villarroel Laura McKain Yulan Li Rachel B Wagman Elizabeth A Stewart Source Type: research
Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas
CONCLUSION: Improvements in heavy menstrual bleeding and anemia and reduction of uterine leiomyoma-associated symptom burden were sustained through up to 52 weeks of treatment with relugolix combination therapy in women with uterine leiomyomas. No new safety concerns were identified, and BMD was maintained.CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov, NCT03049735; NCT03103087; NCT03412890.FUNDING SOURCE: Myovant Sciences GmbH.PMID:36357960 | DOI:10.1097/AOG.0000000000004988 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - November 11, 2022 Category: OBGYN Authors: Ayman Al-Hendy Andrea S Lukes Alfred N Poindexter Roberta Venturella Claudio Villarroel Laura McKain Yulan Li Rachel B Wagman Elizabeth A Stewart Source Type: research
Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas
CONCLUSION: Improvements in heavy menstrual bleeding and anemia and reduction of uterine leiomyoma-associated symptom burden were sustained through up to 52 weeks of treatment with relugolix combination therapy in women with uterine leiomyomas. No new safety concerns were identified, and BMD was maintained.CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov, NCT03049735; NCT03103087; NCT03412890.FUNDING SOURCE: Myovant Sciences GmbH.PMID:36357960 | DOI:10.1097/AOG.0000000000004988 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - November 11, 2022 Category: OBGYN Authors: Ayman Al-Hendy Andrea S Lukes Alfred N Poindexter Roberta Venturella Claudio Villarroel Laura McKain Yulan Li Rachel B Wagman Elizabeth A Stewart Source Type: research
Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas
CONCLUSION: Improvements in heavy menstrual bleeding and anemia and reduction of uterine leiomyoma-associated symptom burden were sustained through up to 52 weeks of treatment with relugolix combination therapy in women with uterine leiomyomas. No new safety concerns were identified, and BMD was maintained.CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov, NCT03049735; NCT03103087; NCT03412890.FUNDING SOURCE: Myovant Sciences GmbH.PMID:36357960 | DOI:10.1097/AOG.0000000000004988 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - November 11, 2022 Category: OBGYN Authors: Ayman Al-Hendy Andrea S Lukes Alfred N Poindexter Roberta Venturella Claudio Villarroel Laura McKain Yulan Li Rachel B Wagman Elizabeth A Stewart Source Type: research
Efficacy and Safety of Oral GnRH antagonists in Patients with Uterine Fibroids: A Systematic Review
CONCLUSION: Among oral GnRH antagonists, relugolix, elagolix, and linzagolix were safe in patients with uterine fibroids. These drugs, alone and in combination with estradiol/norethindrone acetate (E2/NETA), showed significantly better efficacy than placebo in improving bleeding, discomfort, uterine/leiomyoma sizes, and quality of life in premenopausal patients with symptomatic uterine fibroids. However, more randomized double blind multicenter clinical trials are needed to confirm these results and to see long-term benefits.PMID:36368594 | DOI:10.1016/j.jogc.2022.10.012 (Source: Journal of Obstetrics and Gynaecology Canada : JOGC)
Source: Journal of Obstetrics and Gynaecology Canada : JOGC - November 11, 2022 Category: OBGYN Authors: Rabiya Niaz Memoona Saeed Huda Khan Muhammad Ashar Ali Ahmed Irshad Marium Faiz Alaa Irshad Faraeha Fatima Sameer Altaf Tunio Wajeeha Aiman Source Type: research
Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas
CONCLUSION: Improvements in heavy menstrual bleeding and anemia and reduction of uterine leiomyoma-associated symptom burden were sustained through up to 52 weeks of treatment with relugolix combination therapy in women with uterine leiomyomas. No new safety concerns were identified, and BMD was maintained.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov , NCT03049735; NCT03103087; NCT03412890.FUNDING SOURCE: Myovant Sciences GmbH.PMID:36357960 | PMC:PMC9665945 | DOI:10.1097/AOG.0000000000004988 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - November 11, 2022 Category: OBGYN Authors: Ayman Al-Hendy Andrea S Lukes Alfred N Poindexter Roberta Venturella Claudio Villarroel Laura McKain Yulan Li Rachel B Wagman Elizabeth A Stewart Source Type: research
Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas
CONCLUSION: Improvements in heavy menstrual bleeding and anemia and reduction of uterine leiomyoma-associated symptom burden were sustained through up to 52 weeks of treatment with relugolix combination therapy in women with uterine leiomyomas. No new safety concerns were identified, and BMD was maintained.CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov, NCT03049735; NCT03103087; NCT03412890.FUNDING SOURCE: Myovant Sciences GmbH.PMID:36357960 | PMC:PMC9665945 | DOI:10.1097/AOG.0000000000004988 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - November 11, 2022 Category: OBGYN Authors: Ayman Al-Hendy Andrea S Lukes Alfred N Poindexter Roberta Venturella Claudio Villarroel Laura McKain Yulan Li Rachel B Wagman Elizabeth A Stewart Source Type: research
Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas
CONCLUSION: Improvements in heavy menstrual bleeding and anemia and reduction of uterine leiomyoma-associated symptom burden were sustained through up to 52 weeks of treatment with relugolix combination therapy in women with uterine leiomyomas. No new safety concerns were identified, and BMD was maintained.CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov, NCT03049735; NCT03103087; NCT03412890.FUNDING SOURCE: Myovant Sciences GmbH.PMID:36357960 | PMC:PMC9665945 | DOI:10.1097/AOG.0000000000004988 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - November 11, 2022 Category: OBGYN Authors: Ayman Al-Hendy Andrea S Lukes Alfred N Poindexter Roberta Venturella Claudio Villarroel Laura McKain Yulan Li Rachel B Wagman Elizabeth A Stewart Source Type: research
Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas
CONCLUSION: Improvements in heavy menstrual bleeding and anemia and reduction of uterine leiomyoma-associated symptom burden were sustained through up to 52 weeks of treatment with relugolix combination therapy in women with uterine leiomyomas. No new safety concerns were identified, and BMD was maintained.CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov, NCT03049735; NCT03103087; NCT03412890.FUNDING SOURCE: Myovant Sciences GmbH.PMID:36357960 | PMC:PMC9665945 | DOI:10.1097/AOG.0000000000004988 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - November 11, 2022 Category: OBGYN Authors: Ayman Al-Hendy Andrea S Lukes Alfred N Poindexter Roberta Venturella Claudio Villarroel Laura McKain Yulan Li Rachel B Wagman Elizabeth A Stewart Source Type: research
Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas
CONCLUSION: Improvements in heavy menstrual bleeding and anemia and reduction of uterine leiomyoma-associated symptom burden were sustained through up to 52 weeks of treatment with relugolix combination therapy in women with uterine leiomyomas. No new safety concerns were identified, and BMD was maintained.CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov, NCT03049735; NCT03103087; NCT03412890.FUNDING SOURCE: Myovant Sciences GmbH.PMID:36357960 | PMC:PMC9665945 | DOI:10.1097/AOG.0000000000004988 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - November 11, 2022 Category: OBGYN Authors: Ayman Al-Hendy Andrea S Lukes Alfred N Poindexter Roberta Venturella Claudio Villarroel Laura McKain Yulan Li Rachel B Wagman Elizabeth A Stewart Source Type: research
Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas
CONCLUSION: Improvements in heavy menstrual bleeding and anemia and reduction of uterine leiomyoma-associated symptom burden were sustained through up to 52 weeks of treatment with relugolix combination therapy in women with uterine leiomyomas. No new safety concerns were identified, and BMD was maintained.CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov, NCT03049735; NCT03103087; NCT03412890.FUNDING SOURCE: Myovant Sciences GmbH.PMID:36357960 | DOI:10.1097/AOG.0000000000004988 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - November 11, 2022 Category: OBGYN Authors: Ayman Al-Hendy Andrea S Lukes Alfred N Poindexter Roberta Venturella Claudio Villarroel Laura McKain Yulan Li Rachel B Wagman Elizabeth A Stewart Source Type: research
